Atezolizumab Shows Activity in ASPS

[D.ap]

The phase II trial planned to enroll patients ≥6 years (NCI center) or ≥18 years (all other centers) with histologically confirmed ASPS, including patient with newly diagnosed, unresectable, metastatic, and measurable disease. The patients were also required to show evidence of disease progression. Enrollment criteria included an ECOG performance status of ≤2 or Karnofsky performance status of ≥70%. Patients with central nervous system lesions and HIV-positive patients were allowed; however, patients with a history of autoimmune disease or who had received anti–PD-1/PD-L1 therapy were excluded.


https://www.targetedonc.com/news/atezol ... rt-sarcoma